Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence
Abstract In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected pati...
Saved in:
| Published in | European heart journal. Cardiovascular pharmacotherapy Vol. 7; no. 4; pp. 334 - 345 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
23.07.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract
In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXaIs’ dose rather than patients’ characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXaIs’ underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXaIs. |
|---|---|
| AbstractList | In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXaIs’ dose rather than patients’ characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXaIs’ underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXaIs. Abstract In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXaIs’ dose rather than patients’ characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXaIs’ underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXaIs. In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXaIs' dose rather than patients' characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXaIs' underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXaIs.In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXaIs' dose rather than patients' characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXaIs' underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXaIs. |
| Author | De Ferrari, Gaetano Maria Gibello, Maddalena Marchionni, Niccolò Ferri, Nicola Corsini, Alberto Brunetti, Enrico Isaia, Gianluca Poli, Daniela Bo, Mario |
| Author_xml | – sequence: 1 givenname: Mario orcidid: 0000-0003-2945-0243 surname: Bo fullname: Bo, Mario email: mario.bo@unito.it organization: Section of Geriatrics, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy – sequence: 2 givenname: Alberto orcidid: 0000-0002-9912-9482 surname: Corsini fullname: Corsini, Alberto organization: Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy – sequence: 3 givenname: Enrico orcidid: 0000-0003-2028-2319 surname: Brunetti fullname: Brunetti, Enrico organization: Section of Geriatrics, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy – sequence: 4 givenname: Gianluca surname: Isaia fullname: Isaia, Gianluca organization: Section of Geriatrics, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy – sequence: 5 givenname: Maddalena surname: Gibello fullname: Gibello, Maddalena organization: Section of Geriatrics, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy – sequence: 6 givenname: Nicola orcidid: 0000-0001-8898-7441 surname: Ferri fullname: Ferri, Nicola organization: Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Via Marzolo 5, 35131 Padua, Italy – sequence: 7 givenname: Daniela surname: Poli fullname: Poli, Daniela organization: Centro Trombosi, Cardiothoracovascular Department, A.O.U. Careggi, Largo Brambilla 3, 50134 Florence, Italy – sequence: 8 givenname: Niccolò orcidid: 0000-0002-8101-4695 surname: Marchionni fullname: Marchionni, Niccolò organization: Division of General Cardiology, Cardiothoracovascular Department, Department of Clinical and Experimental Medicine, A.O.U. Careggi, University of Florence, Largo Brambilla 3, 50134 Florence, Italy – sequence: 9 givenname: Gaetano Maria orcidid: 0000-0003-4940-0876 surname: De Ferrari fullname: De Ferrari, Gaetano Maria organization: Division of Cardiology, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32853346$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUFr3DAQhUVJadI01x6LoJfm4ESWZFnurYSmDQRyaSA3M5ZGrBav5Uryhl77y6vtbnMIlJw0I773Zpj3lhxNYUJC3tfsomaduMTV2mzny3kLUDPxipxw1jSV0rI5eqpFe0zOUlozxmqlFdfiDTkWXDdCSHVCft85V40w4EiXhDQ4GtEuBi21ofTWRzSZhggjdWByiPQBqJ9WfvClSaWkaRnWBUr00ecVhRz9DvZD9OMI2YfpM4XiuvX4uPM3o5-8KUj5sTgZfEdeOxgTnh3eU3J__fXH1ffq9u7bzdWX28qIrs3VMHQgLCoE41QnmHLGdqCV6ZoWeAuSKxh0o1BraTmTjW2dax1KbjrOBROn5NPed47h54Ip9xufDJYlJwxL6rkUWrWqrnfox2foOixxKtv1vGmLWd0JWagPB2oZNmj7OfoNxF_9v-sW4GIPmBhSiuiekJr1uwT7fYL9IcEikM8Exue_N8wR_Ph_2fleFpb5pRF_AC-gseg |
| CitedBy_id | crossref_primary_10_1016_j_ejim_2023_10_010 crossref_primary_10_23736_S0031_0808_24_05114_0 crossref_primary_10_1007_s40256_021_00488_4 crossref_primary_10_1007_s11606_024_09106_w crossref_primary_10_4081_btvb_2023_84 crossref_primary_10_1016_j_jamda_2024_01_011 crossref_primary_10_1161_CIRCOUTCOMES_121_007971 crossref_primary_10_3390_jcm13072009 crossref_primary_10_1007_s41999_021_00537_w crossref_primary_10_1111_joim_20044 crossref_primary_10_23736_S0026_4806_21_07525_X |
| Cites_doi | 10.1253/circj.CJ-18-1282 10.1186/s12872-020-01340-4 10.1093/ehjcvp/pvy041 10.1007/s40267-019-00696-8 10.1007/s00380-019-01457-3 10.1161/CIRCULATIONAHA.110.004747 10.1093/eurheartj/ehy731 10.1016/j.joa.2017.05.008 10.1016/j.amjmed.2019.09.026 10.1016/j.ejim.2017.03.012 10.1111/jth.14001 10.1016/j.amjcard.2020.01.044 10.1007/s00415-020-09795-3 10.1002/joa3.12231 10.1007/s40256-018-0310-3 10.1016/j.cgh.2014.11.007 10.1161/STROKEAHA.119.025623 10.1177/1074248418821712 10.1136/bmjopen-2019-031341 10.1016/j.jacc.2015.09.024 10.1177/0091270006296058 10.1002/clc.22949 10.1001/jama.2018.17242 10.1016/j.ijcard.2015.03.334 10.1007/s40262-013-0100-7 10.1161/JAHA.119.014108 10.1016/j.jjcc.2019.07.007 10.1007/s11239-019-01934-6 10.1161/CIRCULATIONAHA.119.041296 10.1177/1060028017726795 10.1056/NEJMoa1107039 10.1371/journal.pone.0216831 10.1002/psp4.12347 10.1093/eurheartj/ehy136 10.1111/bcp.13631 10.1253/circj.CJ-18-0991 10.1161/CIRCULATIONAHA.118.036248 10.1080/03007995.2016.1237937 10.1001/jamacardio.2017.0364 10.1038/s41598-020-58665-5 10.1080/03007995.2019.1647735 10.1001/jamainternmed.2016.3057 10.1016/j.jstrokecerebrovasdis.2018.07.028 10.1016/j.amjmed.2017.11.007 10.1186/s40780-020-0157-z 10.1038/ajg.2017.39 10.1016/j.amjmed.2019.01.025 10.1016/j.jacc.2014.05.065 10.1016/j.acvd.2019.02.003 10.18549/PharmPract.2019.4.1709 10.1161/STROKEAHA.119.025350 10.1007/s11239-019-01815-y 10.1177/8755122517706423 10.1161/STROKEAHA.118.024210 10.1161/JAHA.117.007603 10.1016/j.jocn.2019.03.037 10.1002/clc.23235 10.1161/JAHA.117.007633 10.1016/j.jacc.2014.02.549 10.1007/s40262-014-0228-0 10.1093/europace/eux316 10.3349/ymj.2019.60.3.277 10.4081/gc.2016.6120 10.1161/STROKEAHA.112.664144 10.1016/j.beha.2013.07.011 10.1111/jth.14457 10.1161/CIRCULATIONAHA.113.004747 10.1016/S0140-6736(14)61943-7 10.1093/eurheartj/ehy170 10.1093/eurheartj/ehy802 10.1160/TH13-09-0734 10.1016/j.jacc.2017.03.600 10.1016/S0735-1097(10)60038-1 10.1111/jcpt.12999 10.1111/joim.12683 10.1056/NEJMoa0905561 10.1016/j.ejim.2019.10.026 10.1111/bcp.12114 10.1186/s40560-016-0144-5 10.1093/eurheartj/ehr342 10.1016/j.jjcc.2016.11.013 10.1016/j.jjcc.2018.09.003 10.1093/ageing/afv156 10.1111/bcp.14127 10.1056/NEJMoa1310907 10.1111/bcp.14116 10.1053/j.gastro.2014.06.007 10.1056/NEJMoa1009638 10.1016/j.ahj.2019.10.013 10.3389/fphar.2018.01220 10.1007/s00228-013-1510-z 10.1016/j.jacc.2013.11.013 10.1093/eurheartj/ehu046 10.1001/jama.2017.13883 10.1016/j.amjcard.2019.02.060 10.1001/jamacardio.2018.3945 10.4070/kcj.2017.0389 10.1016/j.jacc.2016.09.966 10.1161/CIRCOUTCOMES.117.003998 10.1111/bcp.12106 10.1016/j.jacc.2019.12.060 10.1001/jamacardio.2016.1829 |
| ContentType | Journal Article |
| Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020 – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1093/ehjcvp/pvaa103 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE ProQuest One Academic Middle East (New) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2055-6845 |
| EndPage | 345 |
| ExternalDocumentID | 32853346 10_1093_ehjcvp_pvaa103 10.1093/ehjcvp/pvaa103 |
| Genre | Journal Article Review |
| GroupedDBID | 0R~ 1TH 3V. 4.4 48X 53G 5WD 7X7 88E 8FI 8FJ AABZA AACZT AAJQQ AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABNHQ ABPQP ABPTD ABQLI ABQNK ABUWG ABWST ABXVV ADBBV ADGZP ADHKW ADIPN ADQBN ADRTK ADVEK AETBJ AEWNT AFFZL AFKRA AFOFC AFXEN AGINJ AGQXC AGUTN AHMBA AJEEA ALIPV ALMA_UNASSIGNED_HOLDINGS ATGXG AVWKF BAYMD BCRHZ BENPR BEYMZ BHONS BPHCQ BTRTY BVXVI C45 CCPQU CDBKE DAKXR EBS EJD ENERS FECEO FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC H13 HMCUK IAO KBUDW KOP KSI KSN M1P MHKGH NOMLY NOYVH O9- OAUYM OAWHX OCZFY ODMLO OJZSN OPAEJ OVD OWPYF PAFKI PEELM PQQKQ PROAC PSQYO ROX RUSNO RXO TEORI TJX UKHRP YAYTL YKOAZ YXANX AAYXX ABEJV ABGNP ABVGC ADNBA ADPDF AEMQT AFXAL AHGBF AJNCP ALXQX AMNDL CITATION IHR ITC NU- PHGZM PHGZT RPM TOX AHMMS CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PUEGO 7X8 |
| ID | FETCH-LOGICAL-c397t-bb9a3de6eacf69306fcd9a86c957a27a426ab856e884d2045d7ff7fe42c922303 |
| IEDL.DBID | 7X7 |
| ISSN | 2055-6837 2055-6845 |
| IngestDate | Fri Jul 11 03:59:05 EDT 2025 Sat Aug 23 13:25:15 EDT 2025 Wed Feb 19 02:27:09 EST 2025 Tue Jul 01 01:13:56 EDT 2025 Thu Apr 24 22:59:23 EDT 2025 Wed Aug 28 03:20:31 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Direct oral anticoagulants Oral anticoagulant therapy Off-label dosing Non-valvular atrial fibrillation Reduced doses Underdosing |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c397t-bb9a3de6eacf69306fcd9a86c957a27a426ab856e884d2045d7ff7fe42c922303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8101-4695 0000-0003-2028-2319 0000-0001-8898-7441 0000-0002-9912-9482 0000-0003-4940-0876 0000-0003-2945-0243 |
| OpenAccessLink | https://academic.oup.com/ehjcvp/article-pdf/7/4/334/39317037/pvaa103.pdf |
| PMID | 32853346 |
| PQID | 2572301934 |
| PQPubID | 2046366 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2438676110 proquest_journals_2572301934 pubmed_primary_32853346 crossref_primary_10_1093_ehjcvp_pvaa103 crossref_citationtrail_10_1093_ehjcvp_pvaa103 oup_primary_10_1093_ehjcvp_pvaa103 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-23 |
| PublicationDateYYYYMMDD | 2021-07-23 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European heart journal. Cardiovascular pharmacotherapy |
| PublicationTitleAlternate | Eur Heart J Cardiovasc Pharmacother |
| PublicationYear | 2021 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Buchholz (2021072618094098200_pvaa103-B23) 2018; 41 Eschler (2021072618094098200_pvaa103-B50) 2020; 133 Bo (2021072618094098200_pvaa103-B54) 2020; 71 Frost (2021072618094098200_pvaa103-B98) 2013; 76 Bo (2021072618094098200_pvaa103-B53) 2017; 41 Chang (2021072618094098200_pvaa103-B84) 2017; 318 Healey (2021072618094098200_pvaa103-B8) 2010; 55 Barco (2021072618094098200_pvaa103-B91) 2013; 26 Angel (2021072618094098200_pvaa103-B16) 2019; 85 Gibson (2021072618094098200_pvaa103-B15) 2018; 52 Aisenberg (2021072618094098200_pvaa103-B75) 2018; 11 Lee (2021072618094098200_pvaa103-B38) 2019; 50 Masclee (2021072618094098200_pvaa103-B82) 2014; 147 van Rein (2021072618094098200_pvaa103-B83) 2019; 139 Woo (2021072618094098200_pvaa103-B90) 2019; 64 Harder (2021072618094098200_pvaa103-B6) 2013; 69 Fox (2021072618094098200_pvaa103-B65) 2011; 32 Sato (2021072618094098200_pvaa103-B25) 2018; 27 Mueck (2021072618094098200_pvaa103-B102) 2014; 53 Abraham (2021072618094098200_pvaa103-B79) 2013; 128 Flaker (2021072618094098200_pvaa103-B73) 2012; 43 Essien (2021072618094098200_pvaa103-B61) 2018; 3 Hirsh Raccah (2021072618094098200_pvaa103-B96) 2019; 47 Bo (2021072618094098200_pvaa103-B93) 2015; 187 Testa (2021072618094098200_pvaa103-B58) 2019; 17 García Rodríguez (2021072618094098200_pvaa103-B33) 2019; 9 Brodie (2021072618094098200_pvaa103-B77) 2018; 131 Ieko (2021072618094098200_pvaa103-B5) 2016; 4 Moudallel (2021072618094098200_pvaa103-B24) 2018; 9 Garcia (2021072618094098200_pvaa103-B71) 2020; 221 Sheikh-Taha (2021072618094098200_pvaa103-B42) 2019; 19 Connolly (2021072618094098200_pvaa103-B1) 2009; 361 Goodman (2021072618094098200_pvaa103-B64) 2014; 63 Tellor (2021072618094098200_pvaa103-B21) 2017; 33 Cho (2021072618094098200_pvaa103-B20) 2020; 125 Patel (2021072618094098200_pvaa103-B2) 2011; 365 Kartas (2021072618094098200_pvaa103-B37) 2019; 24 Badreldin (2021072618094098200_pvaa103-B43) 2020; 36 Eikelboom (2021072618094098200_pvaa103-B95) 2017; 2 Yagi (2021072618094098200_pvaa103-B46) 2020; 35 Ono (2021072618094098200_pvaa103-B41) 2019; 73 Halvorsen (2021072618094098200_pvaa103-B68) 2014; 35 Umei (2021072618094098200_pvaa103-B27) 2017; 33 Ray (2021072618094098200_pvaa103-B85) 2018; 320 Franchi (2021072618094098200_pvaa103-B19) 2018; 84 Dalgaard (2021072618094098200_pvaa103-B72) 2020; 141 Sakaguchi (2021072618094098200_pvaa103-B57) 2017; 70 Lee (2021072618094098200_pvaa103-B47) 2020; 10 Cangemi (2021072618094098200_pvaa103-B78) 2017; 112 Lanas (2021072618094098200_pvaa103-B80) 2015; 13 Malik (2021072618094098200_pvaa103-B92) 2019; 123 Paciaroni (2021072618094098200_pvaa103-B87) 2019; 50 Eikelboom (2021072618094098200_pvaa103-B9) 2011; 123 Zeitouni (2021072618094098200_pvaa103-B69) 2020; 75 Gustafson (2021072618094098200_pvaa103-B34) 2019; 17 Coleman (2021072618094098200_pvaa103-B60) 2016; 32 Kubitza (2021072618094098200_pvaa103-B100) 2007; 47 Jang (2021072618094098200_pvaa103-B36) 2019; 44 Sherwood (2021072618094098200_pvaa103-B63) 2015; 66 Steffel (2021072618094098200_pvaa103-B55) 2018; 39 Cheng (2021072618094098200_pvaa103-B31) 2019; 50 McAlister (2021072618094098200_pvaa103-B17) 2018; 7 Ablefoni (2021072618094098200_pvaa103-B28) 2019; 42 Navarro-Almenzar (2021072618094098200_pvaa103-B49) 2019; 35 Staerk (2021072618094098200_pvaa103-B11) 2018; 283 Miyazaki (2021072618094098200_pvaa103-B48) 2020; 6 Wang (2021072618094098200_pvaa103-B66) 2019; 40 Lip (2021072618094098200_pvaa103-B10) 2014; 111 Santos (2021072618094098200_pvaa103-B14) 2020; 86 Killu (2021072618094098200_pvaa103-B52) 2019; 40 Cirincione (2021072618094098200_pvaa103-B101) 2018; 7 Granger (2021072618094098200_pvaa103-B3) 2011; 365 Ikeda (2021072618094098200_pvaa103-B35) 2019; 48 Bo (2021072618094098200_pvaa103-B81) 2016; 2 Testa (2021072618094098200_pvaa103-B97) 2018; 16 Murata (2021072618094098200_pvaa103-B40) 2019; 83 Stoll (2021072618094098200_pvaa103-B89) 2020; 267 Upreti (2021072618094098200_pvaa103-B99) 2013; 76 Poli (2021072618094098200_pvaa103-B88) 2019; 14 Yao (2021072618094098200_pvaa103-B22) 2017; 69 Steinberg (2021072618094098200_pvaa103-B26) 2018; 7 Suwa (2021072618094098200_pvaa103-B59) 2019; 83 Hylek (2021072618094098200_pvaa103-B67) 2014; 63 Steinberg (2021072618094098200_pvaa103-B13) 2016; 68 Inoue (2021072618094098200_pvaa103-B45) 2020; 75 Lee (2021072618094098200_pvaa103-B62) 2018; 48 Cuker (2021072618094098200_pvaa103-B56) 2014; 64 Falissard (2021072618094098200_pvaa103-B32) 2019; 112 Frost (2021072618094098200_pvaa103-B94) 2015; 54 Briasoulis (2021072618094098200_pvaa103-B44) 2020; 20 Giugliano (2021072618094098200_pvaa103-B4) 2013; 369 Shinohara (2021072618094098200_pvaa103-B86) 2019; 35 Kooistra (2021072618094098200_pvaa103-B51) 2016; 176 Ruff (2021072618094098200_pvaa103-B76) 2015; 385 Lee (2021072618094098200_pvaa103-B39) 2019; 60 Ruiz Ortiz (2021072618094098200_pvaa103-B12) 2018; 20 Sanghai (2021072618094098200_pvaa103-B18) 2020; 9 Steffel (2021072618094098200_pvaa103-B7) 2018; 39 Arbel (2021072618094098200_pvaa103-B30) 2019; 132 Amarenco (2021072618094098200_pvaa103-B29) 2019; 5 Ng (2021072618094098200_pvaa103-B74) 2016; 45 Alexander (2021072618094098200_pvaa103-B70) 2016; 1 |
| References_xml | – volume: 83 start-page: 991 year: 2019 ident: 2021072618094098200_pvaa103-B59 article-title: Rivaroxaban or apixaban for non-valvular atrial fibrillation—efficacy and safety of off-label under-dosing according to plasma concentration publication-title: Circ J doi: 10.1253/circj.CJ-18-1282 – volume: 20 start-page: 42 year: 2020 ident: 2021072618094098200_pvaa103-B44 article-title: Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-020-01340-4 – volume: 5 start-page: 70 year: 2019 ident: 2021072618094098200_pvaa103-B29 article-title: Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvy041 – volume: 36 start-page: 83 year: 2020 ident: 2021072618094098200_pvaa103-B43 article-title: Prevalence and predictors of inappropriate apixaban dosing in patients with non-valvular atrial fibrillation at a large tertiary academic medical institution publication-title: Drugs Ther Perspect doi: 10.1007/s40267-019-00696-8 – volume: 35 start-page: 110 year: 2020 ident: 2021072618094098200_pvaa103-B46 article-title: Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation publication-title: Heart Vessels doi: 10.1007/s00380-019-01457-3 – volume: 123 start-page: 2363 year: 2011 ident: 2021072618094098200_pvaa103-B9 article-title: Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.110.004747 – volume: 40 start-page: 1294 year: 2019 ident: 2021072618094098200_pvaa103-B52 article-title: Risk stratification for stroke in atrial fibrillation: a critique publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy731 – volume: 33 start-page: 475 year: 2017 ident: 2021072618094098200_pvaa103-B27 article-title: Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients publication-title: J Arrhythm doi: 10.1016/j.joa.2017.05.008 – volume: 133 start-page: 599 year: 2020 ident: 2021072618094098200_pvaa103-B50 article-title: Oral anticoagulation in patients in the emergency department: high rates of off-label doses, no difference in bleeding rates publication-title: Am J Med doi: 10.1016/j.amjmed.2019.09.026 – volume: 41 start-page: 18 year: 2017 ident: 2021072618094098200_pvaa103-B53 article-title: Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2017.03.012 – volume: 16 start-page: 842 year: 2018 ident: 2021072618094098200_pvaa103-B97 article-title: Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants publication-title: J Thromb Haemost doi: 10.1111/jth.14001 – volume: 125 start-page: 1332 year: 2020 ident: 2021072618094098200_pvaa103-B20 article-title: Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2020.01.044 – volume: 267 start-page: 2007 year: 2020 ident: 2021072618094098200_pvaa103-B89 article-title: Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation publication-title: J Neurol doi: 10.1007/s00415-020-09795-3 – volume: 35 start-page: 795 year: 2019 ident: 2021072618094098200_pvaa103-B86 article-title: Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty publication-title: J Arrhythm doi: 10.1002/joa3.12231 – volume: 19 start-page: 195 year: 2019 ident: 2021072618094098200_pvaa103-B42 article-title: Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA: a chart review of 909 patients publication-title: Am J Cardiovasc Drugs doi: 10.1007/s40256-018-0310-3 – volume: 13 start-page: 906 year: 2015 ident: 2021072618094098200_pvaa103-B80 article-title: Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.11.007 – volume: 50 start-page: 2574 year: 2019 ident: 2021072618094098200_pvaa103-B31 article-title: Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation publication-title: Stroke doi: 10.1161/STROKEAHA.119.025623 – volume: 24 start-page: 225 year: 2019 ident: 2021072618094098200_pvaa103-B37 article-title: Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge publication-title: J Cardiovasc Pharmacol Ther doi: 10.1177/1074248418821712 – volume: 9 start-page: e031341 year: 2019 ident: 2021072618094098200_pvaa103-B33 article-title: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK publication-title: BMJ Open doi: 10.1136/bmjopen-2019-031341 – volume: 66 start-page: 2271 year: 2015 ident: 2021072618094098200_pvaa103-B63 article-title: Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.09.024 – volume: 47 start-page: 218 year: 2007 ident: 2021072618094098200_pvaa103-B100 article-title: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects publication-title: J Clin Pharmacol doi: 10.1177/0091270006296058 – volume: 41 start-page: 671 year: 2018 ident: 2021072618094098200_pvaa103-B23 article-title: Initial apixaban dosing in patients with atrial fibrillation publication-title: Clin Cardiol doi: 10.1002/clc.22949 – volume: 320 start-page: 2221 year: 2018 ident: 2021072618094098200_pvaa103-B85 article-title: Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding publication-title: JAMA doi: 10.1001/jama.2018.17242 – volume: 187 start-page: 123 year: 2015 ident: 2021072618094098200_pvaa103-B93 article-title: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2015.03.334 – volume: 53 start-page: 1 year: 2014 ident: 2021072618094098200_pvaa103-B102 article-title: Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban publication-title: Clin Pharmacokinet doi: 10.1007/s40262-013-0100-7 – volume: 9 start-page: e014108 year: 2020 ident: 2021072618094098200_pvaa103-B18 article-title: Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study publication-title: J Am Heart Assoc doi: 10.1161/JAHA.119.014108 – volume: 75 start-page: 208 year: 2020 ident: 2021072618094098200_pvaa103-B45 article-title: Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the STANDARD study publication-title: J Cardiol doi: 10.1016/j.jjcc.2019.07.007 – volume: 48 start-page: 653 year: 2019 ident: 2021072618094098200_pvaa103-B35 article-title: Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-019-01934-6 – volume: 141 start-page: 10 year: 2020 ident: 2021072618094098200_pvaa103-B72 article-title: Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.041296 – volume: 52 start-page: 54 year: 2018 ident: 2021072618094098200_pvaa103-B15 article-title: Assessment of apixaban prescribing patterns for nonvalvular atrial fibrillation in hospitalized patients publication-title: Ann Pharmacother doi: 10.1177/1060028017726795 – volume: 365 start-page: 981 year: 2011 ident: 2021072618094098200_pvaa103-B3 article-title: Apixaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1107039 – volume: 14 start-page: e0216831 year: 2019 ident: 2021072618094098200_pvaa103-B88 article-title: Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study publication-title: PLoS One doi: 10.1371/journal.pone.0216831 – volume: 7 start-page: 728 year: 2018 ident: 2021072618094098200_pvaa103-B101 article-title: Population Pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12347 – volume: 39 start-page: 1330 year: 2018 ident: 2021072618094098200_pvaa103-B7 article-title: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy136 – volume: 84 start-page: 2010 year: 2018 ident: 2021072618094098200_pvaa103-B19 article-title: Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13631 – volume: 83 start-page: 727 year: 2019 ident: 2021072618094098200_pvaa103-B40 article-title: Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry publication-title: Circ J doi: 10.1253/circj.CJ-18-0991 – volume: 139 start-page: 775 year: 2019 ident: 2021072618094098200_pvaa103-B83 article-title: Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.036248 – volume: 32 start-page: 2047 year: 2016 ident: 2021072618094098200_pvaa103-B60 article-title: Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study publication-title: Curr Med Res Opin doi: 10.1080/03007995.2016.1237937 – volume: 2 start-page: 566 year: 2017 ident: 2021072618094098200_pvaa103-B95 article-title: Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2017.0364 – volume: 10 start-page: 1801 year: 2020 ident: 2021072618094098200_pvaa103-B47 article-title: Effectiveness and safety of off-label dosing of non-vitamin k antagonist anticoagulant for atrial fibrillation in Asian patients publication-title: Sci Rep doi: 10.1038/s41598-020-58665-5 – volume: 35 start-page: 2035 year: 2019 ident: 2021072618094098200_pvaa103-B49 article-title: Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: refase Registry publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1647735 – volume: 176 start-page: 1176 year: 2016 ident: 2021072618094098200_pvaa103-B51 article-title: Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2016.3057 – volume: 27 start-page: 3280 year: 2018 ident: 2021072618094098200_pvaa103-B25 article-title: The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2018.07.028 – volume: 131 start-page: 573.e9 year: 2018 ident: 2021072618094098200_pvaa103-B77 article-title: Severity of gastrointestinal bleeding in patients treated with direct-acting oral anticoagulants publication-title: Am J Med doi: 10.1016/j.amjmed.2017.11.007 – volume: 6 start-page: 2 year: 2020 ident: 2021072618094098200_pvaa103-B48 article-title: Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study publication-title: J Pharm Health Care Sci doi: 10.1186/s40780-020-0157-z – volume: 112 start-page: 734 year: 2017 ident: 2021072618094098200_pvaa103-B78 article-title: A comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin publication-title: Am J Gastroenterol doi: 10.1038/ajg.2017.39 – volume: 132 start-page: 847 year: 2019 ident: 2021072618094098200_pvaa103-B30 article-title: Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation publication-title: Am J Med doi: 10.1016/j.amjmed.2019.01.025 – volume: 64 start-page: 1128 year: 2014 ident: 2021072618094098200_pvaa103-B56 article-title: Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.05.065 – volume: 112 start-page: 400 year: 2019 ident: 2021072618094098200_pvaa103-B32 article-title: Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: the PAROS cross-sectional study of routine clinical practice publication-title: Arch Cardiovasc Dis doi: 10.1016/j.acvd.2019.02.003 – volume: 17 start-page: 1709 year: 2019 ident: 2021072618094098200_pvaa103-B34 article-title: Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation publication-title: Pharm Pract (Granada) doi: 10.18549/PharmPract.2019.4.1709 – volume: 50 start-page: 2168 year: 2019 ident: 2021072618094098200_pvaa103-B87 article-title: Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention publication-title: Stroke doi: 10.1161/STROKEAHA.119.025350 – volume: 47 start-page: 550 year: 2019 ident: 2021072618094098200_pvaa103-B96 article-title: Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-019-01815-y – volume: 33 start-page: 140 year: 2017 ident: 2021072618094098200_pvaa103-B21 article-title: Evaluation of apixaban for the treatment of nonvalvular atrial fibrillation with regard to dosing and safety in a community hospital publication-title: J Pharm Technol doi: 10.1177/8755122517706423 – volume: 50 start-page: 1140 year: 2019 ident: 2021072618094098200_pvaa103-B38 article-title: Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function publication-title: Stroke doi: 10.1161/STROKEAHA.118.024210 – volume: 7 start-page: e007603 year: 2018 ident: 2021072618094098200_pvaa103-B17 article-title: Use of direct oral anticoagulants in Canadian Primary Care Practice 2010-2015: a cohort study from the Canadian Primary Care Sentinel Surveillance Network publication-title: J Am Heart Assoc doi: 10.1161/JAHA.117.007603 – volume: 64 start-page: 127 year: 2019 ident: 2021072618094098200_pvaa103-B90 article-title: Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2019.03.037 – volume: 42 start-page: 873 year: 2019 ident: 2021072618094098200_pvaa103-B28 article-title: Initial rivaroxaban dosing in patients with atrial fibrillation publication-title: Clin Cardiol doi: 10.1002/clc.23235 – volume: 7 start-page: e007633 year: 2018 ident: 2021072618094098200_pvaa103-B26 article-title: Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II publication-title: J Am Heart Assoc doi: 10.1161/JAHA.117.007633 – volume: 63 start-page: 2141 year: 2014 ident: 2021072618094098200_pvaa103-B67 article-title: Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.02.549 – volume: 54 start-page: 651 year: 2015 ident: 2021072618094098200_pvaa103-B94 article-title: Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0228-0 – volume: 20 start-page: 1577 year: 2018 ident: 2021072618094098200_pvaa103-B12 article-title: Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry publication-title: Europace doi: 10.1093/europace/eux316 – volume: 60 start-page: 277 year: 2019 ident: 2021072618094098200_pvaa103-B39 article-title: Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation publication-title: Yonsei Med J doi: 10.3349/ymj.2019.60.3.277 – volume: 2 start-page: 6120 year: 2016 ident: 2021072618094098200_pvaa103-B81 article-title: Antiplatelet therapy is not a safer alternative to oral anticoagulants, even in older hospital-discharged patients with atrial fibrillation publication-title: Geriatr Care doi: 10.4081/gc.2016.6120 – volume: 43 start-page: 3291 year: 2012 ident: 2021072618094098200_pvaa103-B73 article-title: Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial publication-title: Stroke doi: 10.1161/STROKEAHA.112.664144 – volume: 26 start-page: 215 year: 2013 ident: 2021072618094098200_pvaa103-B91 article-title: New oral anticoagulants in elderly patients publication-title: Best Pract Res Clin Haematol doi: 10.1016/j.beha.2013.07.011 – volume: 17 start-page: 1064 year: 2019 ident: 2021072618094098200_pvaa103-B58 article-title: Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants publication-title: J Thromb Haemost doi: 10.1111/jth.14457 – volume: 128 start-page: 1869 year: 2013 ident: 2021072618094098200_pvaa103-B79 article-title: Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.004747 – volume: 385 start-page: 2288 year: 2015 ident: 2021072618094098200_pvaa103-B76 article-title: Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61943-7 – volume: 39 start-page: 1322 year: 2018 ident: 2021072618094098200_pvaa103-B55 article-title: Ten Commandments’ of the EHRA Guide for the Use of NOACs in AF publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy170 – volume: 40 start-page: 1492 year: 2019 ident: 2021072618094098200_pvaa103-B66 article-title: Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy802 – volume: 111 start-page: 933 year: 2014 ident: 2021072618094098200_pvaa103-B10 article-title: Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database publication-title: Thromb Haemost doi: 10.1160/TH13-09-0734 – volume: 69 start-page: 2779 year: 2017 ident: 2021072618094098200_pvaa103-B22 article-title: Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.03.600 – volume: 55 start-page: A4.E37 year: 2010 ident: 2021072618094098200_pvaa103-B8 article-title: Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(10)60038-1 – volume: 44 start-page: 760 year: 2019 ident: 2021072618094098200_pvaa103-B36 article-title: Factors related to inappropriate edoxaban use publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12999 – volume: 283 start-page: 45 year: 2018 ident: 2021072618094098200_pvaa103-B11 article-title: Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study publication-title: J Intern Med doi: 10.1111/joim.12683 – volume: 361 start-page: 1139 year: 2009 ident: 2021072618094098200_pvaa103-B1 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 71 start-page: 32 year: 2020 ident: 2021072618094098200_pvaa103-B54 article-title: Practical use of direct oral anticoagulants (DOACs) in the older persons with atrial fibrillation publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2019.10.026 – volume: 76 start-page: 908 year: 2013 ident: 2021072618094098200_pvaa103-B99 article-title: Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12114 – volume: 4 start-page: 19 year: 2016 ident: 2021072618094098200_pvaa103-B5 article-title: Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences publication-title: J Intensive Care doi: 10.1186/s40560-016-0144-5 – volume: 32 start-page: 2387 year: 2011 ident: 2021072618094098200_pvaa103-B65 article-title: Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment publication-title: Eur Heart J doi: 10.1093/eurheartj/ehr342 – volume: 70 start-page: 244 year: 2017 ident: 2021072618094098200_pvaa103-B57 article-title: Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban publication-title: J Cardiol doi: 10.1016/j.jjcc.2016.11.013 – volume: 73 start-page: 14 year: 2019 ident: 2021072618094098200_pvaa103-B41 article-title: Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: a cross-sectional analysis of a multicenter outpatient registry publication-title: J Cardiol doi: 10.1016/j.jjcc.2018.09.003 – volume: 45 start-page: 77 year: 2016 ident: 2021072618094098200_pvaa103-B74 article-title: Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial publication-title: Age Ageing doi: 10.1093/ageing/afv156 – volume: 86 start-page: 533 year: 2020 ident: 2021072618094098200_pvaa103-B14 article-title: Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14127 – volume: 369 start-page: 2093 year: 2013 ident: 2021072618094098200_pvaa103-B4 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1310907 – volume: 85 start-page: 2838 year: 2019 ident: 2021072618094098200_pvaa103-B16 article-title: Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14116 – volume: 147 start-page: 784 year: 2014 ident: 2021072618094098200_pvaa103-B82 article-title: Risk of upper gastrointestinal bleeding from different drug combinations publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.06.007 – volume: 365 start-page: 883 year: 2011 ident: 2021072618094098200_pvaa103-B2 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 221 start-page: 1 year: 2020 ident: 2021072618094098200_pvaa103-B71 article-title: Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial publication-title: Am Heart J doi: 10.1016/j.ahj.2019.10.013 – volume: 9 start-page: 1220 year: 2018 ident: 2021072618094098200_pvaa103-B24 article-title: Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing publication-title: Front Pharmacol doi: 10.3389/fphar.2018.01220 – volume: 69 start-page: 1617 year: 2013 ident: 2021072618094098200_pvaa103-B6 article-title: Novel oral anticoagulants: clinical pharmacology, indications and practical considerations publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-013-1510-z – volume: 63 start-page: 891 year: 2014 ident: 2021072618094098200_pvaa103-B64 article-title: Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.11.013 – volume: 35 start-page: 1864 year: 2014 ident: 2021072618094098200_pvaa103-B68 article-title: Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehu046 – volume: 318 start-page: 1250 year: 2017 ident: 2021072618094098200_pvaa103-B84 article-title: Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation publication-title: JAMA doi: 10.1001/jama.2017.13883 – volume: 123 start-page: 2051 year: 2019 ident: 2021072618094098200_pvaa103-B92 article-title: Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2019.02.060 – volume: 3 start-page: 1174 year: 2018 ident: 2021072618094098200_pvaa103-B61 article-title: Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2018.3945 – volume: 48 start-page: 519 year: 2018 ident: 2021072618094098200_pvaa103-B62 article-title: Gender-related differences in management of nonvalvular atrial fibrillation in an Asian population publication-title: Korean Circ J doi: 10.4070/kcj.2017.0389 – volume: 68 start-page: 2597 year: 2016 ident: 2021072618094098200_pvaa103-B13 article-title: Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2016.09.966 – volume: 11 start-page: e003998 year: 2018 ident: 2021072618094098200_pvaa103-B75 article-title: Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction) publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.117.003998 – volume: 76 start-page: 776 year: 2013 ident: 2021072618094098200_pvaa103-B98 article-title: Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12106 – volume: 75 start-page: 1145 year: 2020 ident: 2021072618094098200_pvaa103-B69 article-title: Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE trial publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.12.060 – volume: 1 start-page: 673 year: 2016 ident: 2021072618094098200_pvaa103-B70 article-title: Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.1829 |
| SSID | ssj0001686283 |
| Score | 2.254402 |
| SecondaryResourceType | review_article |
| Snippet | Abstract
In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in... In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXaIs) is quite common in stroke... |
| SourceID | proquest pubmed crossref oup |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 334 |
| SubjectTerms | Administration, Oral Anticoagulants Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Cardiac arrhythmia Drug dosages Factor Xa Inhibitors Humans Off-Label Use Stroke Stroke - diagnosis Stroke - etiology Stroke - prevention & control |
| Title | Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32853346 https://www.proquest.com/docview/2572301934 https://www.proquest.com/docview/2438676110 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fi9QwEA569-KL-NvV8xhFzpcL2yZtmvoiKnccgneL7EHfStqk3MrSrtfdg3v1L3emSXcRUR8KDR1a6Ewyk8nM9zH2Fvdb2uRJzK2wOU-SNOImwmGcWZlWJrLJADz_9VydXSZfirQICbc-lFWOa-KwUNuuphz5FE0Lo2UMN5IPqx-cWKPodDVQaNxl-wRdRiVdWZHtcizU_jAgcYooTbnCzdgWt1FO3dX3-mY1Xd0YE4-cWcEv_dbr9kfIObie0wfsfogZ4aNX8kN2x7WP2NHMg07fHsN810PVH8MRzHZw1LeP2c-LpuGoa7eETe-ga-Ca4FqdBdvh2Ps0oEZ98OQ7UBhYtFeLakFMPHgL_aaidE0PlLUFMzB9QEPNAktfSvceDPgmGHr_2G0JLlCWPmGXpyfzz2c8MC_wGuOTNa-q3EjrFK7KDXElqqa2udGqztPMiMygWzeVTpXTOrEEaG-zpskal4g6x3gjkk_ZXtu17jkDp2MjK1G7KsWdi9RGoyJVLWK6hEwnjI__vawDLDmxYyxLfzwuS6-nMuhpwt5t5VcekOOvkm9Qjf8VOhi1XIbZ25c7W5uw19vHOO_oMMW0rtugTCK1yhRGTxP2zFvH9lNSaOpwVi_-_fKX7J6gCpko40IesL319ca9whBnXR0OdnzI9j-dnM--4Wh-UfwCQqD_rg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wAviDuFAQcE42VWE9txHCSEuGzq2FYq1El9C07saEVVUpZ2qK_8IH4jx3XSCiHgaQ-REuXIkXKOfS72-T5CnmO-pXQiQmqYSagQUUB1gI9hbHiU6cCIFfD8yUD2T8XHcTTeIj_bXhh3rLJdE1cLtalyVyPvoWlhtIzhhngz-0Yda5TbXW0pNLxZHNnld0zZ6teHH1C_Lxg72B-979OGVYDm6HvnNMsSzY2VuOIUjgdQFrlJtJJ5EsWaxRpdls5UJK1SwjiwdhMXRVxYwfIEfWnAcdwrZFtwTGU6ZPvd_mD4eVPVcQ0XK-xPFkQRlZj-rZEiec-efc0vZr3ZhdZhy9LVeMLfuuv-CHJXzu7gBrneRKnw1pvVTbJly1tkd-hhrpd7MNp0bdV7sAvDDQD28jb58akoKFqXncKitlAVcO4AYq0BU-Gz96LgoAHA0_3AWMOkPJtkE8f9g7dQLzJXIKrB1YlBr7hFoHDtCVN_eO8VaPBtN278tr8TbEOSeoecXopW7pJOWZX2PgGrQs0zltsswlyJK63QdGTOQncxHnUJbf97mjdA6I6PY5r6DXmeej2ljZ665OVafuYhQP4q-QzV-F-hnVbLabNe1OnGurvk6fo1znS3faNLWy1QRnAlY4nxWpfc89ax_hRnyvVUywf_HvwJudofnRynx4eDo4fkGnPnc4KYMr5DOvPzhX2EAdY8e9xYNZAvlz2RfgFepTwG |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Off-label+use+of+reduced+dose+direct+oral+factor+Xa+inhibitors+in+subjects+with+atrial+fibrillation%3A+a+review+of+clinical+evidence&rft.jtitle=European+heart+journal.+Cardiovascular+pharmacotherapy&rft.au=Bo%2C+Mario&rft.au=Corsini%2C+Alberto&rft.au=Brunetti%2C+Enrico&rft.au=Isaia%2C+Gianluca&rft.date=2021-07-23&rft.pub=Oxford+University+Press&rft.issn=2055-6837&rft.eissn=2055-6845&rft.volume=7&rft.issue=4&rft.spage=334&rft.epage=345&rft_id=info:doi/10.1093%2Fehjcvp%2Fpvaa103 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-6837&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-6837&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-6837&client=summon |